Karin Jooss
Chief Tech/Sci/R&D Officer bei GRITSTONE BIO, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019.
She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021.
Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016.
Dr. Jooss holds a doctorate degree from Philipps University of Marburg.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0,40% | 01.02.2024 | 395 204 ( 0,40% ) | 1 Mio $ | 31.03.2024 |
FATE THERAPEUTICS, INC.
0,01% | 06.06.2023 | 9 848 ( 0,01% ) | 72 284 $ | 31.03.2024 |
Aktive Positionen von Karin Jooss
| Unternehmen | Position | Beginn |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 13.04.2016 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 14.03.2019 |
Ehemalige bekannte Positionen von Karin Jooss
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01.04.2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 01.04.2009 |
Ausbildung von Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
